Featured Research

from universities, journals, and other organizations

New Platinum-based Anti-tumor Compound Developed

Date:
February 21, 2009
Source:
Wake Forest University
Summary:
Researchers have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

The results were published in the December 11 issue of the Journal of Medicinal Chemistry and highlighted in Science-Business eXchange (SciBX), produced by Nature Publishing Group and BioCentury Publications, Inc. They suggest a new approach to fighting non-small cell lung cancer, which accounts for more than three-quarters of all lung cancers. Lung cancer is the leading cause of cancer-related deaths in both men and women. Less than a third of non-small cell lung cancer patients respond to traditional platinum-based therapies, and those who do respond have a median survival of less than a year.

“We are able to slow the growth of this cancer substantially in mice,” said principal investigator Ulrich Bierbach, Z. Smith Reynolds Foundation Fellow and associate professor of chemistry at Wake Forest. “That is very good news, since this is such a rapidly growing, intractable type of cancer.”

The new compound’s potency derives from its ability to rapidly bind with and disable a tumor cell’s DNA before the cell’s natural repair mechanisms are activated. That repair process causes drug resistance, which reduces the effectiveness of currently used platinum-based drugs.

Bierbach has focused his research efforts since 1992 on finding ways to overcome the resistance problems inherent in platinum-based drugs. He joined the Wake Forest faculty in 1999, and since 2001, has led a research team that included participation by eight graduate students and more than 30 undergraduate students. The recent paper marks the 25th he has published on the topic.

“If this ends up in clinical trials in the next few years, that will fulfill a dream of mine,” Bierbach said.

His research efforts will now be directed toward finding ways to boost the tumor-killing potency of the new compounds while reducing harmful side effects.

The new hybrid compounds are available for licensing from the Wake Forest University Office of Technology Asset Management.


Story Source:

The above story is based on materials provided by Wake Forest University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zhidong Ma, Jayati Roy Choudhury, Marcus W. Wright, Cynthia S. Day, Gilda Saluta, Gregory L. Kucera, Ulrich Bierbach. A Non-Cross-Linking Platinum-Acridine Agent with Potent Activity in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2008; 51 (23): 7574 DOI: 10.1021/jm800900g

Cite This Page:

Wake Forest University. "New Platinum-based Anti-tumor Compound Developed." ScienceDaily. ScienceDaily, 21 February 2009. <www.sciencedaily.com/releases/2009/02/090211193818.htm>.
Wake Forest University. (2009, February 21). New Platinum-based Anti-tumor Compound Developed. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2009/02/090211193818.htm
Wake Forest University. "New Platinum-based Anti-tumor Compound Developed." ScienceDaily. www.sciencedaily.com/releases/2009/02/090211193818.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins